Compare GSK plc (GSK) vs Hut 8 Corp (HUT) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

HUT trades at $96.3, down 2.06% on the day, with a bearish technical signal despite bullish moving averages. The company reported a net loss of $226.15M on $235.12M revenue in 2025, with negative margins, but beat EPS expectations in two of the last three quarters. Recent news highlights its pivot to AI infrastructure, securing $16.8B in contracted revenue and $4.25B in investment-grade financing for data center projects.

The outlook is mixed: strong analyst consensus (93.75% buy ratings) and a $138.89 price target suggest upside, but persistent losses, high valuation ratios, and execution risks in the competitive AI infrastructure space pose significant challenges. The stock's near-term direction hinges on Q2 2026 earnings results and successful scaling of new projects.